Tolerable Treatments Lacking for Higher-Risk Myelodysplastic Syndromes

FRIDAY, Oct. 20, 2023 -- There is a clear, unmet need for tolerable treatments that can produce durable remission among patients with higher-risk myelodysplastic syndromes (HR-MDS), according to a study published online Sept. 7 in Leukemia &...